Company's Profile
Dimerix Limited, headquartered in Australia, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to address unmet medical needs worldwide. The company's primary focus is on advancing its product candidates, DMX-200 and DMX-700, to treat conditions such as Focal Segmental Glomerulosclerosis (FSGS), respiratory complications linked to COVID-19, Diabetic Kidney Disease, and Chronic Obstructive Pulmonary Disease (COPD). These candidates, identified through their proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), offer a scalable platform capable of swiftly identifying new drug opportunities by comprehensively studying receptor interactions. Dimerix targets various global markets, with initial emphasis placed on the United States and Europe. Notably, the company has completed two Phase 2 studies, one for FSGS and another for diabetic kidney disease. Additionally, Dimerix has licensed Receptor-HIT to Excellerate Bioscience.
